Dr. Brentjens [Damon Runyon-Lilly Clinical Investigator] investigates how patients’ immune systems can be directed to recognize and kill their own cancer cells.  He is leading an innovative Phase I trial using patients' own genetically modified immune T cells to treat chronic lymphocytic leukemia (CLL).  He is also initiating a related clinical trial to treat pediatric patients with acute lymphocytic leukemia (ALL).  These are patients for whom all other treatment options have been exhausted.

---

Project Title: "Adoptive therapy of B cell leukemias with genetically modified autologous T cells"

Institution: Memorial Sloan-Kettering Cancer Center

Sponsor(s) / Mentor(s): Michel Sadelain, MD, PhD

Cancer Type: Leukemias

Research Area: Gene Therapy